SG11201901477PA - Compound for use in the treatment of neurogenic orthostatic hypotension - Google Patents
Compound for use in the treatment of neurogenic orthostatic hypotensionInfo
- Publication number
- SG11201901477PA SG11201901477PA SG11201901477PA SG11201901477PA SG11201901477PA SG 11201901477P A SG11201901477P A SG 11201901477PA SG 11201901477P A SG11201901477P A SG 11201901477PA SG 11201901477P A SG11201901477P A SG 11201901477PA SG 11201901477P A SG11201901477P A SG 11201901477PA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- california
- pct
- treatment
- orthostatic hypotension
- Prior art date
Links
- 208000001089 Multiple system atrophy Diseases 0.000 title abstract 3
- 206010031127 Orthostatic hypotension Diseases 0.000 title abstract 3
- 230000001272 neurogenic effect Effects 0.000 title abstract 3
- 150000001875 compounds Chemical class 0.000 title abstract 2
- TZIALEBTHQWNAO-UHFFFAOYSA-N ampreloxetine Chemical compound FC1=CC(F)=CC(F)=C1OCC1=CC=CC=C1C1CCNCC1 TZIALEBTHQWNAO-UHFFFAOYSA-N 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 102220240796 rs553605556 Human genes 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4465—Non condensed piperidines, e.g. piperocaine only substituted in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4425—Pyridinium derivatives, e.g. pralidoxime, pyridostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
- C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 08 March 2018 (08.03.2018) WIPO I PCT (51) International Patent Classification: A61K 31/4465 (2006.01) A61K 31/192 (2006.01) A61K 45/06 (2006.01) A61K 31/44 (2006.01) A61P 9/02 (2006.01) A61K 31/573 (2006.01) A61K 31/165 (2006.01) (21) International Application Number: PCT/US2017/048324 (22) International Filing Date: mu °million °nolo olomomillioolimio oimIE (10) International Publication Number WO 2018/044667 Al (25) Filing Language: (26) Publication Language: (30) Priority Data: 62/381,114 24 August 2017 (24.08.2017) English English 30 August 2016 (30.08.2016) US (71) Applicant: THERAVANCE BIOPHARMA R&D IP, LLC [US/US]; 901 Gateway Boulevard, South San Fran- cisco, California 94080 (US). (72) Inventor: HEGDE, Sharathchandra S.; 20860 Fargo Dri- ve, Cupertino, California 95014 (US). (74) Agent: HAGENAH, Jeffrey A. et al.; Theravance Biophar- ma US, Inc., 901 Gateway Boulevard, South San Francisco, California 94080 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: with international search report (Art. 21(3)) 1-1 O \" (57) : The invention relates to use of 4-[2-(2,4,6-trifluorophenoxymethyl)- phenyl]piperidine or a pharmaceutically-acceptable 0 salt thereof for the treatment of neurogenic orthostatic hypotension and the symptoms thereof. (54) Title: COMPOUND FOR USE IN THE TREATMENT OF NEUROGENIC ORTHOSTATIC HYPOTENSION
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662381114P | 2016-08-30 | 2016-08-30 | |
| PCT/US2017/048324 WO2018044667A1 (en) | 2016-08-30 | 2017-08-24 | Compound for use in the treatment of neurogenic orthostatic hypotension |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201901477PA true SG11201901477PA (en) | 2019-03-28 |
Family
ID=59772789
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201901477PA SG11201901477PA (en) | 2016-08-30 | 2017-08-24 | Compound for use in the treatment of neurogenic orthostatic hypotension |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US10238642B2 (en) |
| EP (1) | EP3506900B1 (en) |
| JP (4) | JP6853345B2 (en) |
| KR (1) | KR102054208B1 (en) |
| CN (3) | CN115770244A (en) |
| AU (1) | AU2017321016B2 (en) |
| BR (1) | BR112019003201A2 (en) |
| CA (1) | CA3032168C (en) |
| CL (1) | CL2019000377A1 (en) |
| CO (1) | CO2019001137A2 (en) |
| DK (1) | DK3506900T3 (en) |
| IL (1) | IL288194B2 (en) |
| MX (1) | MX370970B (en) |
| MY (1) | MY194181A (en) |
| NZ (1) | NZ750392A (en) |
| PH (1) | PH12019500252A1 (en) |
| RU (1) | RU2723095C1 (en) |
| SG (1) | SG11201901477PA (en) |
| TW (1) | TWI731153B (en) |
| WO (1) | WO2018044667A1 (en) |
| ZA (1) | ZA201900640B (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2358675B9 (en) | 2008-11-14 | 2019-09-11 | Theravance, Inc. | 4-[2-(2-Fluorophenoxymethyl)phenyl]piperidine compounds |
| WO2019232010A1 (en) | 2018-06-01 | 2019-12-05 | Theravance Biopharma R&D Ip, Llc | PROCESS FOR PREPARING 2-(1-(tert-BUTOXYCARBONYL)PIPERIDINE-4-YL)BENZOIC ACID |
| WO2020191052A1 (en) * | 2019-03-19 | 2020-09-24 | Cerecor, Inc. | Methods for treating symptomatic orthostatic hypotension |
| WO2021247647A1 (en) * | 2020-06-02 | 2021-12-09 | Mohamed Hussein Hamdan | Sublingual formulation for hypotension and syncope |
| TW202345817A (en) | 2022-03-28 | 2023-12-01 | 美商施萬生物製藥研發 Ip有限責任公司 | Methods for treating a subject having multiple system atrophy |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS56104815A (en) | 1980-01-23 | 1981-08-20 | Sumitomo Chem Co Ltd | Remedy for peripheral orthostatic hypotension |
| AU3760600A (en) | 1999-03-19 | 2000-10-09 | Knoll Pharmaceutical Company | Treatment of orthostatic hypotension |
| WO2008112773A2 (en) | 2007-03-12 | 2008-09-18 | Chelsea Therapeutics, Inc. | Droxidopa and pharmaceutical composition thereof for the treatment of neurally mediated hypotension |
| EP2358675B9 (en) | 2008-11-14 | 2019-09-11 | Theravance, Inc. | 4-[2-(2-Fluorophenoxymethyl)phenyl]piperidine compounds |
| US20130197090A1 (en) | 2012-01-31 | 2013-08-01 | Chelsea Therapeutics, Inc. | Postural stability and incident functions in patients |
| WO2014174425A2 (en) * | 2013-04-24 | 2014-10-30 | Mahesh Kandula | Compositions and methods for the treatment of orthostasis and neurological diseases |
| AU2014287418A1 (en) * | 2013-07-08 | 2016-01-28 | Auspex Pharmaceuticals, Inc. | Dihydroxyphenyl neurotransmitter compounds, compositions and methods |
-
2017
- 2017-08-24 SG SG11201901477PA patent/SG11201901477PA/en unknown
- 2017-08-24 BR BR112019003201A patent/BR112019003201A2/en active Search and Examination
- 2017-08-24 RU RU2019109201A patent/RU2723095C1/en active
- 2017-08-24 JP JP2019511563A patent/JP6853345B2/en active Active
- 2017-08-24 EP EP17761725.5A patent/EP3506900B1/en active Active
- 2017-08-24 MX MX2019001915A patent/MX370970B/en active IP Right Grant
- 2017-08-24 DK DK17761725.5T patent/DK3506900T3/en active
- 2017-08-24 KR KR1020197009073A patent/KR102054208B1/en active IP Right Grant
- 2017-08-24 CN CN202211332857.4A patent/CN115770244A/en active Pending
- 2017-08-24 MY MYPI2019000101A patent/MY194181A/en unknown
- 2017-08-24 NZ NZ750392A patent/NZ750392A/en unknown
- 2017-08-24 AU AU2017321016A patent/AU2017321016B2/en active Active
- 2017-08-24 IL IL288194A patent/IL288194B2/en unknown
- 2017-08-24 CA CA3032168A patent/CA3032168C/en active Active
- 2017-08-24 CN CN202211404261.0A patent/CN115813923A/en active Pending
- 2017-08-24 CN CN201780051586.6A patent/CN109640989A/en active Pending
- 2017-08-24 WO PCT/US2017/048324 patent/WO2018044667A1/en active Application Filing
- 2017-08-24 US US15/685,119 patent/US10238642B2/en active Active
- 2017-08-29 TW TW106129248A patent/TWI731153B/en active
-
2019
- 2019-01-30 ZA ZA201900640A patent/ZA201900640B/en unknown
- 2019-02-04 PH PH12019500252A patent/PH12019500252A1/en unknown
- 2019-02-07 CO CONC2019/0001137A patent/CO2019001137A2/en unknown
- 2019-02-13 CL CL2019000377A patent/CL2019000377A1/en unknown
- 2019-10-21 JP JP2019192017A patent/JP2020023552A/en not_active Withdrawn
-
2021
- 2021-07-16 JP JP2021118135A patent/JP2021167344A/en not_active Withdrawn
-
2023
- 2023-08-31 JP JP2023141033A patent/JP7542121B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201908604YA (en) | Fused imidazo-piperidine jak inhibitor compound | |
| SG11201906891RA (en) | Methods for the administration of certain vmat2 inhibitors | |
| SG11201907034PA (en) | Methods of treating influenza | |
| SG11201901477PA (en) | Compound for use in the treatment of neurogenic orthostatic hypotension | |
| SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
| SG11201907840RA (en) | Fused imidazo-piperidine jak inhibitors | |
| SG11201811470PA (en) | Pyrazolopyrimidine derivatives as kinase inhibitor | |
| SG11201907023UA (en) | Method of reducing neutropenia | |
| SG11201804312RA (en) | Microbubble-chemotherapeutic agent complex for sonodynamic therapy | |
| SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
| SG11201907604UA (en) | Crystalline forms of the 4-pyrimidinesulfamide derivative aprocitentan | |
| SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
| SG11201808222RA (en) | Methods of treatment of cholestatic diseases | |
| SG11201809882XA (en) | Pharmaceutical combinations for treating cancer | |
| SG11201900405XA (en) | Compounds, compositions and methods for treating or preventing a sympton associated with gout or hyperuricemia | |
| SG11201909376TA (en) | Crystalline forms of a jak inhibitor compound | |
| SG11201900633XA (en) | Piperidine cxcr7 receptor modulators | |
| SG11201808525UA (en) | Anti-complement factor bb antibodies and uses thereof | |
| SG11201902949PA (en) | Pharmaceutical compositions and methods of treating cardiovascular diseases | |
| SG11202000333UA (en) | Bicyclic ketone compounds and methods of use thereof | |
| SG11201901438VA (en) | Solid forms of cenicriviroc mesylate and processes of making solid forms of cenicriviroc mesylate | |
| SG11201806133UA (en) | Intermediates in the synthesis of eribulin and related methods of synthesis | |
| SG11201906987RA (en) | Combination of a ppar agonist with a fxr agonist | |
| SG11201811686UA (en) | 18f-labeled triazole containing psma inhibitors | |
| SG11201810934TA (en) | Microparticles comprising a sulphur-containing compound |